IL121165A0 - Pharmaceutical compositions containing carboxylic acids and derivatives thereof - Google Patents

Pharmaceutical compositions containing carboxylic acids and derivatives thereof

Info

Publication number
IL121165A0
IL121165A0 IL12116597A IL12116597A IL121165A0 IL 121165 A0 IL121165 A0 IL 121165A0 IL 12116597 A IL12116597 A IL 12116597A IL 12116597 A IL12116597 A IL 12116597A IL 121165 A0 IL121165 A0 IL 121165A0
Authority
IL
Israel
Prior art keywords
substituted
chain
derivatives
pharmaceutical compositions
alkyl
Prior art date
Application number
IL12116597A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL12116597A priority Critical patent/IL121165A0/xx
Publication of IL121165A0 publication Critical patent/IL121165A0/xx
Priority to IL13354098A priority patent/IL133540A0/xx
Priority to AU77839/98A priority patent/AU7783998A/en
Priority to PCT/IB1998/000968 priority patent/WO1999000116A2/en
Priority to EP98925875A priority patent/EP1001755B1/en
Priority to CA002294232A priority patent/CA2294232A1/en
Priority to RU2000101334/15A priority patent/RU2239427C2/ru
Priority to CN98806550A priority patent/CN1261274A/zh
Priority to CNA2007101516440A priority patent/CN101129349A/zh
Priority to JP50539899A priority patent/JP2002507209A/ja
Priority to AT98925875T priority patent/ATE508739T1/de
Priority to US09/104,880 priority patent/US6303653B1/en
Priority to IL133540A priority patent/IL133540A/en
Priority to US10/735,452 priority patent/US20040171585A1/en
Priority to US10/735,439 priority patent/US20040171688A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12116597A 1997-06-26 1997-06-26 Pharmaceutical compositions containing carboxylic acids and derivatives thereof IL121165A0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IL12116597A IL121165A0 (en) 1997-06-26 1997-06-26 Pharmaceutical compositions containing carboxylic acids and derivatives thereof
AT98925875T ATE508739T1 (de) 1997-06-26 1998-06-23 Carboxylsäuren un deren derivate und pharmazeutische zusammensetzungen die diese enthalten
RU2000101334/15A RU2239427C2 (ru) 1997-06-26 1998-06-23 Карбоновые кислоты и их производные и содержащие их фармацевтические композиции
CNA2007101516440A CN101129349A (zh) 1997-06-26 1998-06-23 羧酸和其衍生物以及含有它们的药物组合物
PCT/IB1998/000968 WO1999000116A2 (en) 1997-06-26 1998-06-23 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
EP98925875A EP1001755B1 (en) 1997-06-26 1998-06-23 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
CA002294232A CA2294232A1 (en) 1997-06-26 1998-06-23 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IL13354098A IL133540A0 (en) 1997-06-26 1998-06-23 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
CN98806550A CN1261274A (zh) 1997-06-26 1998-06-23 羧酸和其衍生物以及含有它们的药物组合物
AU77839/98A AU7783998A (en) 1997-06-26 1998-06-23 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JP50539899A JP2002507209A (ja) 1997-06-26 1998-06-23 カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物
US09/104,880 US6303653B1 (en) 1997-06-26 1998-06-25 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IL133540A IL133540A (en) 1997-06-26 1999-12-15 Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US10/735,452 US20040171585A1 (en) 1997-06-26 2003-12-11 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US10/735,439 US20040171688A1 (en) 1997-06-26 2003-12-11 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12116597A IL121165A0 (en) 1997-06-26 1997-06-26 Pharmaceutical compositions containing carboxylic acids and derivatives thereof

Publications (1)

Publication Number Publication Date
IL121165A0 true IL121165A0 (en) 1997-11-20

Family

ID=11070308

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12116597A IL121165A0 (en) 1997-06-26 1997-06-26 Pharmaceutical compositions containing carboxylic acids and derivatives thereof
IL133540A IL133540A (en) 1997-06-26 1999-12-15 Pharmaceutical compositions containing carboxylic acids and derivatives thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL133540A IL133540A (en) 1997-06-26 1999-12-15 Pharmaceutical compositions containing carboxylic acids and derivatives thereof

Country Status (10)

Country Link
US (1) US6303653B1 (enExample)
EP (1) EP1001755B1 (enExample)
JP (1) JP2002507209A (enExample)
CN (2) CN101129349A (enExample)
AT (1) ATE508739T1 (enExample)
AU (1) AU7783998A (enExample)
CA (1) CA2294232A1 (enExample)
IL (2) IL121165A0 (enExample)
RU (1) RU2239427C2 (enExample)
WO (1) WO1999000116A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
CN1329359C (zh) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
WO2002009691A1 (en) * 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
AU2001290241A1 (en) * 2000-09-20 2002-04-02 Kyowa Hakko Kogyo Co. Ltd. Tumor cell proliferation inhibitors
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
CN1283610C (zh) 2000-10-11 2006-11-08 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
JP2004532799A (ja) 2000-10-11 2004-10-28 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
JP4931349B2 (ja) 2003-01-23 2012-05-16 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
CA2549995C (en) 2003-12-24 2011-11-15 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2550943A1 (en) * 2003-12-30 2005-07-14 Syndrome X Ltd. Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
CN101365446B (zh) 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
WO2007137864A1 (en) * 2006-06-01 2007-12-06 Eucro European Contract Research Gmbh & Co. Kg Use of inhibitors of pp2c for treating or preventing arteriosclerosis
WO2008018877A1 (en) 2006-08-11 2008-02-14 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs, methods of production and uses thereof
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
US8481084B2 (en) 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
DE102007051339A1 (de) * 2007-10-26 2009-04-30 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
ES2532402T3 (es) 2008-06-26 2015-03-26 Resverlogix Corporation Métodos de preparación de derivados de quinazolinona
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
WO2010083311A2 (en) * 2009-01-14 2010-07-22 Vanas Oncology Compositions and methods of use
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
EP2414042A4 (en) * 2009-03-31 2013-01-30 Matthew R Witten RADIATION THERAPY TREATMENT SYSTEM AND METHOD FOR PROVIDING USE OF A MIMETIC OPTIMIZATION ALGORITHM
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US10479752B2 (en) * 2011-12-08 2019-11-19 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US20180092874A1 (en) * 2016-10-03 2018-04-05 Lincoln Memorial University Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
JP7234151B2 (ja) * 2017-07-07 2023-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 脂肪酸誘導体およびこれらの使用
US12344578B2 (en) 2019-06-21 2025-07-01 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
DE4224670A1 (de) 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
ATE183391T1 (de) * 1993-12-31 1999-09-15 Univ Limburg Verwendung von zusammensetzungen essentieller fettsäuren
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
PL343902A1 (en) * 1997-02-21 2001-09-10 Abbott Lab Methods of and compositions for reducing enteritis and colitis morbidity rate

Also Published As

Publication number Publication date
JP2002507209A (ja) 2002-03-05
WO1999000116A3 (en) 1999-08-12
CA2294232A1 (en) 1999-01-07
WO1999000116A2 (en) 1999-01-07
AU7783998A (en) 1999-01-19
EP1001755B1 (en) 2011-05-11
ATE508739T1 (de) 2011-05-15
IL133540A (en) 2009-09-22
EP1001755A2 (en) 2000-05-24
US6303653B1 (en) 2001-10-16
CN1261274A (zh) 2000-07-26
CN101129349A (zh) 2008-02-27
RU2239427C2 (ru) 2004-11-10

Similar Documents

Publication Publication Date Title
IL121165A0 (en) Pharmaceutical compositions containing carboxylic acids and derivatives thereof
HUT64512A (en) Process for preparing acetic acid derivatives containing heteroatom with lipid level reducing activity and pharmaceutical compositions containing them
ATE149485T1 (de) Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DE69420068D1 (de) 1H-Indol-3-Acetamid-Derivate als sPLA2-Inhibitoren
BR9401484A (pt) Hidrazida de ácido 1h-indol-3-acético e formulação farmacêutica
KR910000101A (ko) 효소형성 억제제
EE200000504A (et) Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to
DE3875750D1 (de) Mikrobizide mittel.
GB1320181A (en) Cyclic carboxylic acid derivatives
DE59200387D1 (de) Heterocyclisch substituierte Chinolylmethoxy-Phenylacetamide als Lipoxygenasehemmer.
ES2122303T3 (es) Nuevos agentes antivirales.
CA2202966A1 (en) Mixtures of carboxylic acid salts and carboxylic acid esters and their use as siccatives for oxidatively drying lacquers
ES398802A1 (es) Procedimiento para la preparacion de acidos propionicos sustituidos por fenilo en la posicion 2.
IL134787A0 (en) Acid addition salts of morphine alkaloids and compositions containing the same
GB1111361A (en) 4-phenoxyalkanoic acids and derivatives thereof
KR910004652A (ko) 5-α-환원 효소억제제로서의 3-치환된 니트로-스테로이드 유도체
DE69203164D1 (de) Vorbeugende/therapeutische Zusammensetzung für die Pleuropneumonie des Schweins.
DE69106888D1 (de) Metallcarboxylate.
UA42830C2 (uk) Засіб для профілактики або лікування рестенозу, фармацевтичний препарат для лікування рестенозу, спосіб профілактики або лікування рестенозу
KR900009533A (ko) 아릴아세트산 모노 에스테르 및 그의 제조방법
ATE347545T1 (de) Hydroxyfunktionelle amid-1h-indolderivate aktiv als spla2 inhibitoren
GB1473981A (en) Hydrazino-cephalosporanic acid derivatives
ATE157652T1 (de) Pge1-analoge
NO20020561L (no) Fremgangsmåte for fremstilling av syrer via alfa-klorepoksi- estere
GR3020336T3 (en) Substituted benzoate derivatives